Polycomb-group proteins in hematopoietic stem cell regulation and hematopoietic neoplasms

Leukemia

Volumn 27, Issue 3, 2013, Pages 523-533

  Radulovic V ^a   De Haan, G ^a   Klauke, K ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

hematopoiesis; lymphoma; Polycomb group genes; stem cells

Indexed keywords

BMI1 PROTEIN; HISTONE H3; HISTONE METHYLTRANSFERASE; POLYCOMB REPRESSIVE COMPLEX 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; BIOACCUMULATION; BURKITT LYMPHOMA; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DOWN REGULATION; DROSOPHILA MELANOGASTER; ENZYME ACTIVITY; EPIGENETICS; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HETEROZYGOSITY; HISTONE MODIFICATION; HISTONE UBIQUITINATION; HUMAN; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; CELL CYCLE; CELL DIFFERENTIATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELLS; HUMANS; POLYCOMB-GROUP PROTEINS;

EID: 84875217558     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.368     Document Type: Review

References (146)

1. Lewis EB. A gene complex controlling segmentation in Drosophila. Nature 1978; 276: 565-570.
2. Levine SS, Weiss A, Erdjument-Bromage H, Shao Z, Tempst P, Kingston RE. The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol 2002; 22: 6070-6078.
3. Simon JA, Kingston RE. Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 2009; 10: 697-708.
4. Morey L, Helin K. Polycomb group protein-mediated repression of transcription. Trends Biochem Sci 2010; 35: 323-332.
5. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-1043.
6. Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 2002; 111: 185-196.
7. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 2002; 16: 2893-2905.
8. Kuzmichev A, Jenuwein T, Tempst P, Reinberg D. Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell 2004; 14: 183-193.
9. Nekrasov M, Wild B, Muller J. Nucleosome binding and histone methyltransferase activity of Drosophila PRC2. EMBO Rep 2005; 6: 348-353.
10. Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev 2004; 18: 1592-1605.
11. Margueron R, Li G, Sarma K, Blais A, Zavadil J, Woodcock CL et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 2008; 32: 503-518.
12. Margueron R, Justin N, Ohno K, Sharpe ML, Son J, Drury 3rd WJ et al. Role of the polycomb protein EED in the propagation of repressive histone marks. Nature 2009; 461: 762-767.
13. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 2004; 15: 57-67.
14. Nekrasov M, Klymenko T, Fraterman S, Papp B, Oktaba K, Kocher T et al. Pcl-PRC2 is needed to generate high levels of H3-K27 trimethylation at Polycomb target genes. EMBO J 2007; 26: 4078-4088.
15. Sarma K, Margueron R, Ivanov A, Pirrotta V, Reinberg D. Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo. Mol Cell Biol 2008; 28: 2718-2731.
16. Savla U, Benes J, Zhang J, Jones RS. Recruitment of Drosophila Polycomb-group proteins by Polycomblike, a component of a novel protein complex in larvae. Development 2008; 135: 813-817.
17. Kim H, Kang K, Kim J. AEBP2 as a potential targeting protein for Polycomb Repression Complex PRC2. Nucleic Acids Res 2009; 37: 2940-2950.
18. Li G, Margueron R, Ku M, Chambon P, Bernstein BE, Jarid2 ReinbergD. and PRC2, partners in regulating gene expression. Genes Dev 2010; 24: 368-380.
19. Hunkapiller J, Shen Y, Diaz A, Cagney G, McCleary D, Ramalho-Santos M et al. Polycomb-like 3 promotes polycomb repressive complex 2 binding to CpG islands and embryonic stem cell self-renewal. PLoS Genet 2012; 8: e1002576.
20. Shao Z, Raible F, Mollaaghababa R, Guyon JR, Wu CT, Bender W et al. Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell 1999; 98: 37-46.
21. Vandamme J, Volkel P, Rosnoblet C, Le Faou P, Angrand PO. Interaction proteomics analysis of polycomb proteins defines distinct PRC1 complexes in mammalian cells. Mol Cell Proteomics 2011; 10: 002642.
22. Wang L, Brown JL, Cao R, Zhang Y, Kassis JA, Jones RS. Hierarchical recruitment of polycomb group silencing complexes. Mol Cell 2004; 14: 637-646.
23. Bernstein E, Duncan EM, Masui O, Gil J, Heard E, Allis CD. Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol Cell Biol 2006; 26: 2560-2569.
24. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 2005; 20: 845-854.
25. Breiling A, Turner BM, Bianchi ME, Orlando V. General transcription factors bind promoters repressed by Polycomb group proteins. Nature 2001; 412: 651-655.
26. Stock JK, Giadrossi S, Casanova M, Brookes E, Vidal M, Koseki H et al. Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells. Nat Cell Biol 2007; 9: 1428-1435.
27. Zhou W, Zhu P, Wang J, Pascual G, Ohgi KA, Lozach J et al. Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation. Mol Cell 2008; 29: 69-80.
28. Whitcomb SJ, Basu A, Allis CD, Bernstein E. Polycomb Group proteins: an evolutionary perspective. Trends Genet 2007; 23: 494-502.
29. Senthilkumar R, Mishra RK. Novel motifs distinguish multiple homologues of Polycomb in vertebrates: expansion and diversification of the epigenetic toolkit. BMC Genomics 2009; 10: 549.
30. Volkel P, Le Faou P, Vandamme J, Pira D, Angrand PO. A human Polycomb isoform lacking the Pc box does not participate to PRC1 complexes but forms protein assemblies and represses transcription. Epigenetics 2012; 7: 482-491.
31. Shaver S, Casas-Mollano JA, Cerny RL, Cerutti H. Origin of the polycomb repressive complex 2 and gene silencing by an E(z) homolog in the unicellular alga Chlamydomonas. Epigenetics 2010; 5: 301-312.
32. Hennig L, Derkacheva M. Diversity of Polycomb group complexes in plants: same rules, different players? Trends Genet 2009; 25: 414-423.
33. Butenko Y, Ohad N. Polycomb-group mediated epigenetic mechanisms through plant evolution. Biochim Biophys Acta 2011; 1809: 395-406.
34. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343-349.
35. Le Faou P, Volkel P, Angrand PO. The zebrafish genes encoding the Polycomb repressive complex (PRC) 1. Gene 2011; 475: 10-21.
36. Morey L, Pascual G, Cozzuto L, Roma G, Wutz A, Benitah SA et al. Nonoverlapping functions of the Polycomb group Cbx family of proteins in embryonic stem cells. Cell Stem Cell 2012; 10: 47-62.
37. O'Loghlen A, Munoz-Cabello AM, Gaspar-Maia A, Wu HA, Banito A, Kunowska N et al. MicroRNA regulation of Cbx7 mediates a switch of Polycomb orthologs during ESC differentiation. Cell Stem Cell 2012; 10: 33-46.
38. Gao Z, Zhang J, Bonasio R, Strino F, Sawai A, Parisi F et al. PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol Cell 2012; 45: 344-356.
39. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 1991; 65: 753-763.
40. Jacobs JJ, Kieboom K, Marino S, DePinho RA, Van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999; 397: 164-168.
41. Tetsu O, Ishihara H, Kanno R, Kamiyasu M, Inoue H, Tokuhisa T et al. mel-18 negatively regulates cell cycle progression upon B cell antigen receptor stimulation through a cascade leading to c-myc/cdc25. Immunity 1998; 9: 439-448.
42. Guo W-J, Datta S, Band V, Dimri GP. Mel-18 a Polycomb Group Protein, Regulates Cell Proliferation and Senescence via Transcriptional Repression of Bmi-1 and c-Myc Oncoproteins. Mol Biol Cell 2007; 18: 536-546.
43. Guo WJ, Zeng MS, Yadav A, Song LB, Guo BH, Band V et al. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res 2007; 67: 5083-5089.
44. Vincenz C, Kerppola TK. Different polycomb group CBX family proteins associate with distinct regions of chromatin using nonhomologous protein sequences. Proc Natl Acad Sci USA 2008; 105: 16572-16577.
45. Mousavi K, Zare H, Wang AH, Sartorelli V. Polycomb protein Ezh1 promotes RNA polymerase II elongation. Mol Cell 2012; 45: 255-262.
46. Tavares L, Dimitrova E, Oxley D, Webster J, Poot R, Demmers J et al. RYBP-PRC1 complexes mediate H2A ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3. Cell 2012; 148: 664-678.
47. Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 2008; 32: 491-502.
48. Ezhkova E, Lien W-H, Stokes N, Pasolli HA, Silva JM, Fuchs E. EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev 2011; 25: 485-498.
49. Mochizuki-Kashio M, Mishima Y, Miyagi S, Negishi M, Saraya A, Konuma T et al. Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells. Blood 2011; 118: 6553-6561.
50. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006; 20: 1123-1136.
51. Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, Mikkelsen TS et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 2008; 4: e1000242.
52. Schoeftner S, Sengupta AK, Kubicek S, Mechtler K, Spahn L, Koseki H et al. Recruitment of PRC1 function at the initiation of X inactivation independent of PRC2 and silencing. EMBO J 2006; 25: 3110-3122.
53. Wilkinson FH, Park K, Atchison ML. Polycomb recruitment to DNA in vivo by the YY1 REPO domain. Proc Natl Acad Sci USA 2006; 103: 19296-19301.
54. Klymenko T, Papp B, Fischle W, Kocher T, Schelder M, Fritsch C et al. A Polycomb group protein complex with sequence-specific DNA-binding and selective methyl-lysine-binding activities. Genes Dev 2006; 20: 1110-1122.
55. Woo CJ, Kharchenko PV, Daheron L, Park PJ, Kingston RE. A region of the human HOXD cluster that confers polycomb-group responsiveness. Cell 2010; 140: 99-110.
56. Xi H, Yu Y, Fu Y, Foley J, Halees A, Weng Z. Analysis of overrepresented motifs in human core promoters reveals dual regulatory roles of YY1. Genome Res 2007; 17: 798-806.
57. Deng Z, Cao P, Wan M, Sui G, Yin 1 Yang. A multifaceted protein beyond a transcription factor. Transcription 2010; 1: 81-84.
58. Ross J, Mavoungou L, Bresnick EH, Milot E. GATA-1 utilizes Ikaros and the Polycomb Repressive Complex 2 to suppress Hes1 and to promote erythropoiesis. Mol Cell Biol 2012; 32: 3624-3638.
59. Boulay G, Dubuissez M, Van Rechem C, Forget A, Helin K, Ayrault O et al. Hypermethylated in cancer 1 (HIC1) recruits polycomb repressive complex 2 (PRC2) to a subset of its target genes through interaction with human polycomb-like (hPCL) proteins. J Biol Chem 2012; 1: 10509-10524.
60. Dietrich N, Lerdrup M, Landt E, Agrawal-Singh S, Bak M, Tommerup N et al. RESTmediated recruitment of polycomb repressor complexes in mammalian cells. PLoS Genet 2012; 8: e1002494.
61. Yu M, Mazor T, Huang H, Huang H-T, Kathrein KL, Woo AJ et al. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell 2012; 45: 330-343.
62. Garca E, Marcos-Gutie rrez C, Del Mar Lorente M, Moreno JC, Vidal M. RYBP a new repressor protein that interacts with components of the mammalian Polycomb complex, and with the transcription factor YY1. EMBO J 1999; 18: 3404-3418.
63. Iwama A, Oguro H, Negishi M, Kato Y, Morita Y, Tsukui H et al. Enhanced selfrenewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 2004; 21: 843-851.
64. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003; 423: 302-305.
65. van der Lugt NM, Domen J, Linders K, van Roon M, Robanus-Maandag E, te Riele H et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev 1994; 8: 757-769.
66. Rizo A, Olthof S, Han L, Vellenga E, de Haan G, Schuringa JJ. Repression of BMI1 in normal and leukemic human CD34(\+) cells impairs self-renewal and induces apoptosis. Blood 2009; 114: 1498-1505.
67. Akasaka T, Tsuji K, Kawahira H, Kanno M, Harigaya K, Hu L et al. The role of mel-18, a mammalian Polycomb group gene, during IL-7-dependent proliferation of lymphocyte precursors. Immunity 1997; 7: 135-146.
68. Kajiume T, Ninomiya Y, Ishihara H, Kanno R, Kanno M. Polycomb group gene mel-18 modulates the self-renewal activity and cell cycle status of hematopoietic stem cells. Exp Hematol 2004; 32: 571-578.
69. Lessard J, Baban S, Sauvageau G. Stage-specific expression of polycomb group genes in human bone marrow cells. Blood 1998; 91: 1216-1224.
70. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006; 127: 265-275.
71. Oguro H, Yuan J, Ichikawa H, Ikawa T, Yamazaki S, Kawamoto H et al. Poised lineage specification in multipotential hematopoietic stem and progenitor cells by the polycomb protein Bmi1. Cell Stem Cell 2010; 6: 279-286.
72. Oguro H, Iwama A, Morita Y, Kamijo T, van Lohuizen M, Nakauchi H. Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice. J Exp Med 2006; 203: 2247-2253.
73. Liu J, Cao L, Chen J, Song S, Lee IH, Quijano C et al. Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 2009; 459: 387-392.
74. Ismail IH, Andrin C, McDonald D, Hendzel MJ. BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. J Cell Biol 2010; 191: 45-60.
75. Facchino S, Abdouh M, Chatoo W, Bernier G. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci 2010; 30: 10096-10111.
76. Gieni RS, Ismail IH, Campbell S, Hendzel MJ. Polycomb group proteins in the DNA damage response: a link between radiation resistance and 'stemness'. Cell Cycle 2011; 10: 883-894.
77. Core N, Bel S, Gaunt SJ, Aurrand-Lions M, Pearce J, Fisher A et al. Altered cellular proliferation and mesoderm patterning in Polycomb-M33-deficient mice. Development 1997; 124: 721-729.
78. Raaphorst FM, Otte AP, Meijer CJ. Polycomb-group genes as regulators of mammalian lymphopoiesis. Trends Immunol 2001; 22: 682-690.
79. Kato Y, Koseki H, Vidal M, Nakauchi H, Iwama A. Unique composition of polycomb repressive complex 1 in hematopoietic stem cells. Int J Hematol 2007; 85: 179-181.
80. Forzati F, Federico A, Pallante P, Abbate A, Esposito F, Malapelle U et al. CBX7 is a tumor suppressor in mice and humans. J Clin Invest 2012; 122: 612-623.
81. Scott CL, Gil J, Hernando E, Teruya-Feldstein J, Narita M, Martinez D et al. Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci USA 2007; 104: 5389-5394.
82. Takihara Y, Tomotsune D, Shirai M, Katoh-Fukui Y, Nishii K, Motaleb MA et al. Targeted disruption of the mouse homologue of the Drosophila polyhomeotic gene leads to altered anteroposterior patterning and neural crest defects. Development 1997; 124: 3673-3682.
83. Tokimasa S, Ohta H, Sawada A, Matsuda Y, Kim JY, Nishiguchi S et al. Lack of the Polycomb-group gene rae28 causes maturation arrest at the early B-cell developmental stage. Exp Hematol 2001; 29: 93-103.
84. Ohta H, Sawada A, Kim JY, Tokimasa S, Nishiguchi S, Humphries RK et al. Polycomb group gene rae28 is required for sustaining activity of hematopoietic stem cells. J Exp Med 2002; 195: 759-770.
85. Kim JY, Sawada A, Tokimasa S, Endo H, Ozono K, Hara J et al. Defective long-term repopulating ability in hematopoietic stem cells lacking the Polycomb-group gene rae28. Eur J Haematol 2004; 73: 75-84.
86. Cales C, Roman-Trufero M, Pavon L, Serrano I, Melgar T, Endoh M et al. Inactivation of the polycomb group protein Ring1B unveils an antiproliferative role in hematopoietic cell expansion and cooperation with tumorigenesis associated with Ink4a deletion. Mol Cell Biol 2008; 28: 1018-1028.
87. Majewski IJ, Ritchie ME, Phipson B, Corbin J, Pakusch M, Ebert A et al. Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells. Blood 2010; 116: 731-739.
88. Pan X, Jones M, Jiang J, Zaprazna K, Yu D, Pear W et al. Increased expression of PcG protein YY1 negatively regulates B cell development while allowing accumulation of myeloid cells and LT-HSC cells. PLoS ONE 2012; 7: e30656.
89. De Haan G, Gerrits A. Epigenetic control of hematopoietic stem cell aging the case of Ezh2. Ann NY Acad Sci 2007; 1106: 233-239.
90. Kamminga LM, Bystrykh LV, de Boer A, Houwer S, Douma J, Weersing E et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 2006; 107: 2170-2179.
91. Herrera-Merchan A, Arranz L, Ligos JM, de Molina A, Dominguez O, Gonzalez S. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun 2012; 3: 623.
92. O'Carroll D, Erhardt S, Pagani M, Barton SC, Surani MA, Jenuwein T. The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol 2001; 21: 4330-4336.
93. Su IH, Basavaraj A, Krutchinsky AN, Hobert O, Ullrich A, Chait BT et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol 2003; 4: 124-131.
94. Lessard J, Schumacher A, Thorsteinsdottir U, van Lohuizen M, Magnuson T, Sauvageau G. Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev 1999; 13: 2691-2703.
95. Majewski IJ, Blewitt ME, de Graaf CA, McManus EJ, Bahlo M, Hilton AA et al. Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity. PLoS Biol 2008; 6: e93.
96. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999; 13: 2678-2690.
97. Oguro H, Yuan J, Tanaka S, Miyagi S, Mochizuki-Kashio M, Ichikawa H et al. Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes. J Exp Med 2012; 209: 445-454.
98. Martin-Perez D, Piris MA, Sanchez-Beato M. Polycomb proteins in hematologic malignancies. Blood 2010; 116: 5465-5475.
99. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010; 7: 299-313.
100. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991; 65: 737-752.
101. Mihara K, Chowdhury M, Nakaju N, Hidani S, Ihara A, Hyodo H et al. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood 2006; 107: 305-308.
102. Xu F, Li X, Wu L, Zhang Q, Yang R, Yang Y et al. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol 2011; 90: 643-653.
103. Chowdhury M, Mihara K, Yasunaga S, Ohtaki M, Takihara Y, Kimura A. Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia 2007; 21: 1116-1122.
104. Mohty M, Yong AS, Szydlo RM, Apperley JF, Melo JV. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007; 110: 380-383.
105. Yong AS, Stephens N, Weber G, Li Y, Savani BN, Eniafe R et al. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein. Leukemia 2011; 25: 629-637.
106. Raaphorst FM, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 2000; 157: 709-715.
107. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001; 97: 3896-3901.
108. Ma Y, Cui W, Yang J, Qu J, Di C, Amin HM et al. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood 2006; 108: 2726-2735.
109. Yang J, Chai L, Liu F, Fink LM, Lin P, Silberstein LE et al. Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci USA 2007; 104: 10494-10499.
110. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 1998; 17: 3714-3725.
111. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423: 255-260.
112. Yuan J, Takeuchi M, Negishi M, Oguro H, Ichikawa H, Iwama A. Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells. Leukemia 2011; 25: 1335-1343.
113. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818-822.
114. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
115. Rizo A, Horton SJ, Olthof S, Dontje B, Ausema A, van Os R et al. BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34\+ cells. Blood 2010; 116: 4621-4630.
116. Sengupta A, Ficker AM, Dunn SK, Madhu M, Cancelas JA. Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells. Blood 2012; 119: 494-502.
117. Dukers DF, van Galen JC, Giroth C, Jansen P, Sewalt RG, Otte AP et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 2004; 164: 873-881.
118. Raaphorst FM, Vermeer M, Fieret E, Blokzijl T, Dukers D, Sewalt RG et al. Sitespecific expression of polycomb-group genes encoding the HPC-HPH/PRC1 complex in clinically defined primary nodal and cutaneous large B-cell lymphomas. Am J Pathol 2004; 164: 533-542.
119. Grubach L, Juhl-Christensen C, Rethmeier A, Olesen LH, Aggerholm A, Hokland P et al. Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol 2008; 81: 112-122.
120. Tan J, Jones M, Koseki H, Nakayama M, Muntean AG, Maillard I et al. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell 2011; 20: 563-575.
121. Garcia-Cuellar MP, Zilles O, Schreiner SA, Birke M, Winkler TH, Slany RK. The ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein recruits human Polycomb 3. Oncogene 2001; 20: 411-419.
122. Wang SS, Menashe I, Cerhan JR, Cozen W, Severson RK, Davis S et al. Variations in chromosomes 9 and 6p21.3 with risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2011; 20: 42-49.
123. Sanchez-Beato M, Sanchez E, Gonzalez-Carrero J, Morente M, Diez A, Sanchez-Verde L et al. Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Mod Pathol 2006; 19: 684-694.
124. Raimondi SC, Shurtleff SA, Downing JR, Rubnitz J, Mathew S, Hancock M et al. 12p abnormalities and the TEL gene (ETV6) in childhood acute lymphoblastic leukemia. Blood 1997; 90: 4559-4566.
125. Sato Y, Bohlander SK, Kobayashi H, Reshmi S, Suto Y, Davis EM et al. Heterogeneity in the breakpoints in balanced rearrangements involving band 12p13 in hematologic malignancies identified by fluorescence in situ hybridization: TEL (ETV6 ) is involved in only one half. Blood 1997; 90: 4886-4893.
126. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998; 91: 3995-4019.
127. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
128. Bodor C, O'Riain C, Wrench D, Matthews J, Iyengar S, Tayyib H et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia 2011; 25: 726-729.
129. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA 2010; 107: 20980-20985.
130. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108-112.
131. Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18: 298-301.
132. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163.
133. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-726.
134. Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665-667.
135. Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011; 118: 5227-5234.
136. Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 2012; 119: 1208-1213.
137. Hock H. A complex Polycomb issue: the two faces of EZH2 in cancer. Genes Dev 2012; 26: 751-755.
138. Simon C, Chagraoui J, Krosl J, Gendron P, Wilhelm B, Lemieux S et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev 2012; 26: 651-656.
139. Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci USA 2012; 109: 5028-5033.
140. Cedar H, Bergman Y. Epigenetics of haematopoietic cell development. Nat Rev Immunol 2011; 11: 478-488.
141. Donohoe ME, Zhang X, McGinnis L, Biggers J, Li E, Shi Y. Targeted disruption of mouse Yin Yang 1 transcription factor results in peri-implantation lethality. Mol Cell Biol 1999; 19: 7237-7244.
142. Faust C, Schumacher A, Holdener B, Magnuson T. The eed mutation disrupts anterior mesoderm production in mice. Development 1995; 121: 273-285.
143. Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J 2004; 23: 4061-4071.
144. Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001; 112: 950-958.
145. Richie ER, Schumacher A, Angel JM, Holloway M, Rinchik EM, Magnuson T. The Polycomb-group gene eed regulates thymocyte differentiation and suppresses the development of carcinogen-induced T-cell lymphomas. Oncogene 2002; 21: 299-306.
146. Sauvageau M, Miller M, Lemieux S, Lessard J, Hebert J, Sauvageau G. Quantitative expression profiling guided by common retroviral insertion sites reveals novel and cell type specific cancer genes in leukemia. Blood 2008; 111: 790-799.